Morgan Stanley downgrades J&J, Merck and Amgen, sees limited upside from here

Employees walk past a Merck sign in front of the company's building in Summit, N.J.
Getty Images

Morgan Stanley is backing away from some large-cap pharmaceutical stocks, saying in note to clients Tuesday that investors should hunt for upside elsewhere.

More In Street Calls

CNBC ProHere are Thursday's biggest analyst calls of the day: Apple, Amazon, Nio, Dave & Buster's and more
CNBC ProWolfe downgrades Ford amid EV push, says stock's surge will slow in 2022
CNBC ProMorgan Stanley says buy the dip in Simon Property Group, with upside of more than 20%